Literature DB >> 20719984

Field evaluation of the efficacy of Mycobacterium bovis bacillus Calmette-Guerin against bovine tuberculosis in neonatal calves in Ethiopia.

Gobena Ameni1, Martin Vordermeier, Abraham Aseffa, Douglas B Young, R Glyn Hewinson.   

Abstract

In developing countries, the conventional test and slaughter strategy for the control of bovine tuberculosis is prohibitively expensive, and alternative control methods such as vaccination are urgently required. In this study, the efficacy of Mycobacterium bovis bacillus Calmette-Guérin (BCG) for protection against bovine tuberculosis (bTB) was evaluated in Holstein calves under field conditions in Ethiopia. Thirteen neonatally vaccinated and 14 control calves were exposed for 10 to 23 months to skin test reactor cows. Gamma interferon (IFN-γ) testing, comparative intradermal tuberculin testing, postmortem examination, and bacteriological culture were used for the evaluation of BCG efficacy. The overall mean pathology score was significantly (P < 0.05) higher in control calves than in vaccinated calves. Culture positivity for Mycobacterium bovis was higher in the control calves than in the vaccinated calves, and significantly more BCG-vaccinated animals would have passed a standard meat inspection (P = 0.021). Overall, the protective efficacy of BCG was between 56% and 68%, depending on the parameters selected. Moreover, by measuring gamma interferon responses to the antigens ESAT-6 and CFP-10, which are present in M. bovis but absent from BCG, throughout the experiment, we were able to distinguish between vaccinated animals that were protected against bTB and those animals that were not protected. In conclusion, the present trial demonstrated an encouraging protective effect of BCG against bTB in a natural transmission setting in Ethiopia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20719984      PMCID: PMC2953002          DOI: 10.1128/CVI.00222-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  20 in total

1.  An experiment to challenge the resistance to tuberculosis in B.C.G. vaccinated cattle in Malawi.

Authors:  F G Waddington; D C Ellwood
Journal:  Br Vet J       Date:  1972-11

2.  Field evaluation of vaccine efficacy.

Authors:  W A Orenstein; R H Bernier; T J Dondero; A R Hinman; J S Marks; K J Bart; B Sirotkin
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

Review 3.  Identification of immune response correlates for protection against bovine tuberculosis.

Authors:  Bryce M Buddle; D Neil Wedlock; Michel Denis; Margot A Skinner
Journal:  Vet Immunol Immunopathol       Date:  2005-10-18       Impact factor: 2.046

4.  Field experiment with BCG vaccine in Malawi.

Authors:  S A Berggren
Journal:  Br Vet J       Date:  1981-01

5.  [Comparative values of live or killed BCG and trypsinized Koch's bacillus in the immunization of zebu against tuberculosis].

Authors:  Y Cheneau; J Blancou
Journal:  Rev Elev Med Vet Pays Trop       Date:  1975

6.  Incidence of tuberculosis in BCG vaccinated and control cattle in relation to age distribution in Malawi.

Authors:  S A Berggren
Journal:  Br Vet J       Date:  1977 Sep-Oct

7.  Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis.

Authors:  H Martin Vordermeier; Mark A Chambers; Paul J Cockle; Adam O Whelan; Jennifer Simmons; R Glyn Hewinson
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

8.  Association of tuberculin-boosted antibody responses with pathology and cell-mediated immunity in cattle vaccinated with Mycobacterium bovis BCG and infected with M. bovis.

Authors:  Konstantin Lyashchenko; Adam O Whelan; Rena Greenwald; John M Pollock; Peter Andersen; R Glyn Hewinson; H Martin Vordermeier
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae.

Authors:  B M Buddle; D Keen; A Thomson; G Jowett; A R McCarthy; J Heslop; G W De Lisle; J L Stanford; F E Aldwell
Journal:  Res Vet Sci       Date:  1995-07       Impact factor: 2.534

10.  Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG.

Authors:  B M Buddle; G W de Lisle; A Pfeffer; F E Aldwell
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

View more
  24 in total

1.  Bacillus Calmette-Guérin vaccination reduces the severity and progression of tuberculosis in badgers.

Authors:  Mark A Chambers; Fiona Rogers; Richard J Delahay; Sandrine Lesellier; Roland Ashford; Deanna Dalley; Sonya Gowtage; Dipesh Davé; Si Palmer; Jacky Brewer; Timothy Crawshaw; Richard Clifton-Hadley; Steve Carter; Chris Cheeseman; Chris Hanks; Alistair Murray; Kate Palphramand; Stéphane Pietravalle; Graham C Smith; Alexandra Tomlinson; Neil J Walker; Gavin J Wilson; Leigh A L Corner; Stephen P Rushton; Mark D F Shirley; George Gettinby; Robbie A McDonald; R Glyn Hewinson
Journal:  Proc Biol Sci       Date:  2010-12-01       Impact factor: 5.349

2.  Duration of immunity against Mycobacterium bovis following neonatal vaccination with bacillus Calmette-Guérin Danish: significant protection against infection at 12, but not 24, months.

Authors:  M L Thom; M McAulay; H M Vordermeier; D Clifford; R G Hewinson; B Villarreal-Ramos; J C Hope
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

Review 3.  Tuberculosis vaccines and prevention of infection.

Authors:  Thomas R Hawn; Tracey A Day; Thomas J Scriba; Mark Hatherill; Willem A Hanekom; Thomas G Evans; Gavin J Churchyard; James G Kublin; Linda-Gail Bekker; Steven G Self
Journal:  Microbiol Mol Biol Rev       Date:  2014-12       Impact factor: 11.056

4.  Subcutaneous administration of a 10-fold-lower dose of a commercial human tuberculosis vaccine, Mycobacterium bovis bacillus Calmette-Guerin Danish, induced levels of protection against bovine tuberculosis and responses in the tuberculin intradermal test similar to those induced by a standard cattle dose.

Authors:  Bryce M Buddle; R Glyn Hewinson; H Martin Vordermeier; D Neil Wedlock
Journal:  Clin Vaccine Immunol       Date:  2013-08-07

5.  The intractable challenge of evaluating cattle vaccination as a control for bovine Tuberculosis.

Authors:  Andrew James Kerr Conlan; Martin Vordermeier; Mart Cm de Jong; James Ln Wood
Journal:  Elife       Date:  2018-06-05       Impact factor: 8.140

6.  Efficacy of a vaccine formula against tuberculosis in cattle.

Authors:  Germinal J Canto Alarcon; Yezenia Rubio Venegas; Luis Bojorquez Narvaez; Oscar E Pizano Martínez; Leticia García Casanova; Susana Sosa Gallegos; Alejandro Nava Vargas; Andrea M Olvera Ramírez; Feliciano Milian Suazo
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

7.  Revaccination of cattle with bacille Calmette-Guérin two years after first vaccination when immunity has waned, boosted protection against challenge with Mycobacterium bovis.

Authors:  Natalie A Parlane; Dairu Shu; Supatsak Subharat; D Neil Wedlock; Bernd H A Rehm; Geoffrey W de Lisle; Bryce M Buddle
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

8.  Immunogenicity of a recombinant Mycobacterium smegmatis vaccine expressing the fusion protein CMX in cattle from Goiás State, Brazil.

Authors:  Duanne Alves Da Silva; Marcos Antônio Rocha Cavalcanti; Fábio Muniz De Oliveira; Monalisa Martins Trentini; Ana Paula Junqueira-Kipnis; André Kipnis
Journal:  J Vet Med Sci       Date:  2014-03-31       Impact factor: 1.267

Review 9.  Epidemiology, diagnostics, and management of tuberculosis in domestic cattle and deer in New Zealand in the face of a wildlife reservoir.

Authors:  B M Buddle; G W de Lisle; J F T Griffin; S A Hutchings
Journal:  N Z Vet J       Date:  2015-02-03       Impact factor: 1.628

Review 10.  The lack of a big picture in tuberculosis: the clinical point of view, the problems of experimental modeling and immunomodulation. The factors we should consider when designing novel treatment strategies.

Authors:  Cristina Vilaplana; Pere-Joan Cardona
Journal:  Front Microbiol       Date:  2014-02-14       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.